The major aspects of the management of patients with acute coronary syndromes described
in this European Society of Cardiology (ESC) Guideline are summarized in Figure 1.

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Background Comparisons between ticagrelor and clopidogrel for the secondary prevention
of stroke in CYP2C19 loss-of-function carriers have not been extensively performed …

CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with …

Importance Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was
evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Importance After percutaneous coronary intervention (PCI), patients withCYP2C19* 2or*
3loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …